Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)

Anaptysbio filings provide 3 years of Non-Current Deffered Revenue readings, the most recent being $171000.0 for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0, compared with a TTM value of $171000.0 through Dec 2018, up 22.14%, and an annual FY2018 reading of $171000.0, up 22.14% over the prior year.
  • Non-Current Deffered Revenue hit $171000.0 in Q4 2018 for Anaptysbio, up from $162000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $171000.0 in Q4 2018, with the low at $128000.0 in Q2 2018.
  • Median Non-Current Deffered Revenue over the past 3 years was $154000.0 (2016), compared with a mean of $151555.6.
  • The largest YoY upside for Non-Current Deffered Revenue was 22.14% in 2018 against a maximum downside of 23.81% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $154000.0 in 2016, then dropped by 9.09% to $140000.0 in 2017, then grew by 22.14% to $171000.0 in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $171000.0, $162000.0, and $128000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.